Enroll in a Study
End-Stage Renal Disease & Dialysis
BD-Connect (ESRD)
Study Details
24 Months
Patient Information
Are you 18 years of age or older with chronic kidney disease stages 3-5 and indicated for arteriovenous fistula (AVF) creation?
This study is focused on evaluating the efficacy and safety of the WavelinQ™ EndoAVF System, a novel technology designed to create an arteriovenous fistula (AVF) for patients needing hemodialysis.
Your participation can help us better understand how the WavelinQ™ EndoAVF System works and its potential to improve the process of creating AVFs, which are essential for hemodialysis patients.
Throughout the study, you will receive detailed and attentive medical care from our experienced research team. This includes regular health assessments, monitoring, and support to ensure your safety and well-being.
Our research team is available to answer any questions you may have and provide further details about the study. Participation is voluntary, and deciding not to participate will not affect your current or future medical care in any way. All information collected during the study will be kept confidential.
If you are interested to participate in this study, sign up today.
Physician Information
Target population: Adult subjects at least 18 years of age who have established, non-reversible kidney failure, who are currently on dialysis.
The problem: While effective, surgical AVF creation can be associated with certain drawbacks, including longer recovery times, increased risk of complications such as infection or bleeding.
Why the problem exists: AVFs have been created surgically by connecting an artery to a vein, usually in the forearm.
New approach to solve the problem: Creation of arteriovenous fistulas (AVFs) for vascular access. The WavelinQ™ EndoAVF System does not cut apart the vessels and does not require them to be moved. There is no surgery that cuts open the area, it leaves the nearby tissues unharmed. Unlike the traditional surgical procedure, the vessels are not sewn together.
Study: A Prospective, Multi-Center Clinical Study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis (CONNECT-AV)
24 Months
Study purpose: To further demonstrate the safety and effectiveness of the creation of an AVF with the WavelinQ™ EndoAVF System.
Sponsor Name: Bard Peripheral Vascular, Inc. (BD Peripheral Intervention)
PI(s): Dr. Osman Khawar
MERCK
Study Details
Approximately 20 months
Patient Information
Are you 18 years of age or older with ESRD receiving hemodialysis via an arteriovenous graft? By participating, you will be at the forefront of medical research aimed at preventing arteriovenous graft thrombosis, a common and serious complication for patients with end-stage renal disease (ESRD) undergoing hemodialysis.
Your involvement can help us evaluate the effectiveness and safety of MK-2060, potentially leading to improved treatment options for patients worldwide.
Throughout the study, you will receive high-quality medical care from our dedicated research team. This includes regular health assessments, monitoring, and support, ensuring that your well-being is closely observed and managed.
Our research team is available to answer any questions you may have and provide further details about the study. Participation is voluntary, and deciding not to participate will not affect your current or future medical care in any way. All information collected during the study will be kept confidential.
If you are interested to participate in this study, sign up today.
Physician Information
Target population: Adult subjects ≥18 years Patients with ESRD receiving hemodialysis via an arteriovenous graft.
The problem: ESRD patients, specifically those on hemodialysis, carry an elevated risk for thrombotic events with associated morbidity and mortality. The relative risk in dialysis patients compared to the general population is >5 fold for MI, ~6 fold for ischemic stroke, and ~2.2 fold for VTE.
Why the problem exists: This tendency to thrombosis is particularly problematic for ESRD patients receiving hemodialysis via an AVG. Successful hemodialysis relies on brisk blood flow through the AVG. AVGs are prone to developing thrombi, which often lead to AVG failure, with annual rates of AVG failure from thrombosis of >50%.
New approach to solve the problem: MK2060 drug for prevention.
Study: A Randomized Parallel-group, Placebo-controlled, Double-blind, Event driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis.
Study duration: Approximately 20 months
Study purpose: Prevention of arteriovenous graft thrombosis.
Sponsor Name: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the Sponsor or MSD)
PI(s): Dr. Berenji, Dr. Boiskin, Dr. Fadda, Dr. Meyer & Dr. Hebreo
Pathalys
Study Details
28 Weeks
Patient Information
Are you between 18 and 80 years of age with ESKD and SHPT on hemodialysis?
By participating in this trial, you will contribute to advancing medical science in the treatment of secondary hyperparathyroidism (SHPT), a common complication in patients with end-stage kidney disease (ESKD) undergoing hemodialysis. Your involvement will help us evaluate the effectiveness and safety of PLS240, potentially leading to improved treatment options for many individuals.
Participants in this study will have access to PLS240, an investigational medication designed to manage SHPT. Throughout the study, you will receive detailed medical care from our dedicated research team. This includes regular health assessments, monitoring, and support to ensure your well-being and to closely observe the effects of the treatment.
Our research team is available to answer any questions you may have and provide further details about the study. Participation is voluntary, and deciding not to participate will not affect your current or future medical care in any way. All information collected during the study will be kept confidential.
If you are interested to participate in this study, sign up today.
Physician Information
Target population: Adult subjects between 18 and 80 years. ESKD participants with history of secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis.
The problem: PTH levels in patients with secondary hyperparathyroidism (SHPT), namely
calcimimetics and active Vitamin D sterols (e.g., calcitriol or Vitamin D analogs).
Why the problem exists: Active Vitamin D sterols are effective in lowering PTH levels; however, their use is associated with elevated Ca and P concentrations in the blood due to increased absorption in the intestine. Because of the dose limits caused by these elevations, active Vitamin D sterols often do not provide optimal therapeutic effects.
New approach to solve the problem: Parathyroid hormone (PTH), produced by parathyroid cells, acts on the kidneys to increase renal calcium (Ca) resorption, and inhibit inorganic phosphate (P) resorption, and also increases the production of activated Vitamin D, thereby promoting the absorption of Ca in the intestine. It is also a hormone that maintains the homeostasis of Ca and P in the body by its action on the bone to promote bone resorption. Decreased Ca concentrations increased P concentrations, and decreased activated Vitamin D concentrations in the blood increase PTH secretion.
Study: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals with End Stage Kidney Disease on Hemodialysis (PATH-2) with an Open-Label Extension
Study duration: 28 weeks
New intervention: There are two main approaches to control PTH levels in patients with secondary hyperparathyroidism (SHPT), namely calcimimetics and active Vitamin D sterols (e.g., calcitriol or Vitamin D analogs).
Study purpose: This trial investigates whether PLS240 may be a beneficial treatment in the hemodialysis population in the United States and globally.
Sponsor Name: Pathalys Pharma, Inc.
PI(s): Dr. Ramin Berenji, Dr. Mark Boiskin, Dr. George Fadda & Dr. Jill Meyer
Sign Up Today
If you have questions about Balboa Research,
please complete the contact form or call
George Nilsson, Clinical Research Director.
George Nilsson
Clinical Research Director
(858) 810-8072